Hosted on MSN

Phase 2 trial reveals potential of DPP-1 inhibitor for bronchiectasis

In March 2025, The Lancet Respiratory Medicine published a phase 2 clinical study article on China's first DPP-1 inhibitor, HSK31858, led by Academician Nan-shan Zhong and Professor Wei-jie Guan from ...
The Diplomat

For Taiwan’s DPP, an Unprecedented ‘3-peat’ Depends on a Third Party

Goodbye New START: How China’s Rise Ended Nuclear Arms Control With Taiwan’s January 2024 presidential elections fast approaching, the field of candidates has taken shape. From the incumbent ...
EurekAlert!

Breakthrough of DPP-1 Inhibitor in decreasing the exacerbation frequency of bronchiectasis (Lancet Respir Med)

Bronchiectasis is one of the most common highly heterogeneous chronic inflammatory airway diseases in China. It has a long course, heavy symptom burden, and is prone to recurrent acute exacerbations, ...